Modulation of expression of monocyte/macrophage plasminogen activator activity and its implications for attenuation of vasculopathy.
- 1 October 1994
- journal article
- abstracts
- Published by Wolters Kluwer Health in Circulation
- Vol. 90 (4) , 1927-1934
- https://doi.org/10.1161/01.cir.90.4.1927
Abstract
BACKGROUND: The binding of urokinase-type plasminogen activator (uPA) to its receptor (uPAR) on cell surfaces has the potential to influence degradation of extracellular matrix (ECM). Thus, uPA bound to monocyte/macrophages and its interactions with plasminogen activator inhibitors types 1 and 2 (PAI-1 and PAI-2) may modify atherogenesis by altering cell-associated proteolytic activity, degradation of ECM, and neointimal formation at sites of vascular injury. METHODS AND RESULTS: To determine whether the expression of proteins on the surface of cells involved in fibrinolysis changes in human cells in response to mediators implicated in atherogenesis, we exposed U937 cells (an immortal human monocyte-like cell line) to transforming growth factor-beta (TGF-beta) and to thrombin. Induction of uPAR mRNA occurred with TGF-beta (5 ng/mL) in a time-dependent fashion (P = .05; n = 4). Thrombin (5 National Institutes of Health [NIH] U/mL) increased uPAR mRNA by 2.8-fold above control (n = 4) without altering PAI-1 mRNA or protein synthesis (n = 4). The increase in uPAR gene expression in cells exposed to either TGF-beta or thrombin translated into a functional increase in cell-surface proteolytic activity. Under control conditions, U937 cells expressed PAI-2 but not PAI-1 mRNA. PAI-2 mRNA expression increased (P < .05; n = 4) with thrombin (5 NIH U/mL) but was suppressed by TGF-beta (5 ng/mL). TGF-beta induced PAI-1 mRNA within 6 hours accompanied by a 9-fold increase in PAI-1 protein from 6 hours (2.9 +/- 1.9 ng/mL) to 24 hours (20.0 +/- 9.6 ng/mL, P = .005; n = 3) paralleled by increased synthesis as shown in metabolic labeling experiments with 35S-methionine and immunoprecipitation of labeled PAI-1. PAI-1 mRNA and protein expression were seen in human coronary artery atherectomy specimens as well and were localized to analogous monocyte/macrophages and to smooth muscle cells as judged from results of in situ hybridization and immunocytochemistry studies. CONCLUSIONS: The results indicate that there is induction of PAI-1 and uPAR in U937 cells exposed to TGF-beta and thrombin. In atheroma, analogous processes may modulate early migration of luminal monocytes into the subintimal space and proteolysis of ECM. Thus, cell surface, monocyte-directed fibrinolysis may influence atherosclerosis, restenosis, or both.Keywords
This publication has 29 references indexed in Scilit:
- Cytokines induce urokinase-dependent adhesion of human myeloid cells. A regulatory role for plasminogen activator inhibitors.Journal of Clinical Investigation, 1993
- Human monocytes can produce tissue-type plasminogen activator.The Journal of Experimental Medicine, 1989
- Urokinase-type plasminogen activator is induced in migrating capillary endothelial cells.The Journal of cell biology, 1987
- Secretory products of macrophages.Journal of Clinical Investigation, 1987
- cDNA cloning and expression in E. coli of a plasminogen activator inhibitor (PAI) related to a PAI produced by Hep G2 hepatoma cellFEBS Letters, 1987
- Urokinase binding sites on human foreskin cells. Evidence for occupancy with endogenous urokinaseBiochemical and Biophysical Research Communications, 1985
- Identification of macrophages and smooth muscle cells in human atherosclerosis using monoclonal antibodiesThe Journal of Pathology, 1985
- Immunocytochemical localization of urokinase-type plasminogen activator in Lewis lung carcinoma.The Journal of cell biology, 1984
- Studies of hypercholesterolemia in the nonhuman primate. I. Changes that lead to fatty streak formation.Arteriosclerosis: An Official Journal of the American Heart Association, Inc., 1984
- Establishment and characterization of a human histiocytic lymphoma cell line (U‐937)International Journal of Cancer, 1976